What is BioCryst Pharmaceuticals's EV / sales?

BioCryst Pharmaceuticals (BCRX) reported EV / sales of 3× in Q1 2026.

How has BioCryst Pharmaceuticals's EV / sales changed year-over-year?

BioCryst Pharmaceuticals's EV / sales decreased by 16.6% year-over-year, from 3.6× to 3×.

What is the long-term trend for BioCryst Pharmaceuticals's EV / sales?

Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's EV / sales has grown at a -51.6% compound annual growth rate (CAGR), from 67.3× to 1.8×.

What does EV / sales mean?

Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.

BioCryst Pharmaceuticals BCRX EV / sales

EV / sales at other companies

Ionis PharmaceuticalsIONS

12.2×+5.7×

Ultragenyx PharmaceuticalRARE

2.7×-4.0×

ANI PharmaceuticalsANIP

1.9×-0.5×

AnaptysBio, Inc.ANAB

5.8×+1.4×

BridgeBio PharmaBBIO

28.9×-18.5×

Arrowhead ResearchARWR

14×+10.9×

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

enterprise value/total revenue=3×

Based on the most recent quarter.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's EV / sales?: BioCryst Pharmaceuticals (BCRX) reported EV / sales of 3× in Q1 2026.
How has BioCryst Pharmaceuticals's EV / sales changed year-over-year?: BioCryst Pharmaceuticals's EV / sales decreased by 16.6% year-over-year, from 3.6× to 3×.
What is the long-term trend for BioCryst Pharmaceuticals's EV / sales?: Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's EV / sales has grown at a -51.6% compound annual growth rate (CAGR), from 67.3× to 1.8×.
What does EV / sales mean?: Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.